PubMed Health⌕ Search

Biomedical subjects

Akio Urabe

Publications and source records attributed to Akio Urabe.

6 recordsLinked to original sources
PubMed2003

[Simultaneous occurrence of acute myeloid leukemia with multilineage dysplasia and multiple myeloma].

An 82-year-old woman was admitted to our hospital because of dizziness and petechiae. Peripheral blood examination showed severe anemia and thrombocytopenia. Bone marrow aspiration revealed 42% leukemic blasts positive for peroxidase with multilineage dysplasia, leading to a diagnosis of acute myeloid leukemia with multilineage dysplasia. The levels of the patient's marrow plasma cells increased to 12%, whereas serum levels of IgG, A, and M dropped. lambda type Bence Jones protein was detected on urine immunoelectrophoresis. The total urinary protein was 3, 960 mg/day. Bone scintigraphy detected multifocal uptake in the ribs. The diagnosis was multiple myeloma developing simultaneously with acute myeloid leukemia. Possible mechanisms for the occurrence of acute myeloid leukemia and multiple myeloma were discussed.

Aged↗
PubMed2003

[Refractory idiopathic thrombocytopenic purpura].

Chronic refractory idiopathic purpura(ITP) is defined as ITP with persistent thrombocytopenia despite conventional initial management with corticosteroids and splenectomy. The goal of treatment is not cure of the ITP, but only to achieve a safe platelet count, which is arbitrarily assumed to be greater than 30,000/mm3. The risk for major bleeding seems great only when the platelet count is less than 10,000/mm3. There is no accepted algorithm for management of patients with chronic refractory ITP. Recently, more targeted therapies including rituximab, anti-CD40 ligand and Campath-1H have been evaluated in refractory ITP.

Humans↗
PubMed2003

[Bone marrow suppression].

Bone marrow suppression is one of the most popular side effects of cancer chemotherapy. Bone marrow suppression includes neutropenia, anemia and thrombocytopenia. Clinical application of cytokine is useful in the treatment of bone marrow suppression due to cancer chemotherapy. Granulocyte colony-stimulating factor(G-CSF) is useful in the treatment of neutropenia. Erythropoietin(EPO) is useful is the treatment of anemia. However, EPO is not widely used in Japan yet. Clinical application of varions cytokines will bring forth much improvement in the treatment of bone marrow suppression due to cancer chemotherapy.

Anemia↗
PubMed2003

[Imatinib].

Imatinib mesylate is an inhibitor of Bcr/Abl tyrosine kinase, which essentially participates the pathogenesis of chronic myelogenous leukemia (CML). Imatinib is highly effective in the treatment of CML. Because imatinib also inhibits c-kit and platelet-derived growth-factor (PDGF) receptor, it may be efficacious against some tumors which possess c-kit or PDGF receptors.

Antineoplastic Agents↗
PubMed2002

Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study.

To investigate the efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in patients with acute myelogenous leukaemia, a multicentre randomized study was performed. From October 1993 to September 1996, 270 patients with newly diagnosed acute myelogenous leukaemia were randomized to G-CSF or control groups after remission induction therapy. The G-CSF group received G-CSF (Filgrastim) from 48 h after the completing chemotherapy until the absolute neutrophil count exceeded 1.5 x 10(9)/l. The control group did not receive G-CSF unless severe infection occurred. There were 245 evaluable patients (120 and 125 in the G-CSF and control groups respectively). The complete remission rate was similar in the G-CSF and control groups (80.8% versus 76.8%), as was the 5-year probability of disease-free survival (34.5% versus 33.6%) and overall survival (42.7% versus 35.6%). Neutrophil recovery was significantly faster in the G-CSF group than in the control group (12 d versus 18 d, P = 0.0001). The median duration of febrile neutropenia was significantly shorter in the G-CSF group than in the control group (3 d versus 4 d, P = 0.0001). In conclusion, prophylactic administration of G-CSF after remission induction therapy for acute myelogenous leukaemia is safe and useful even in patients without infection on completing chemotherapy.

Adolescent↗